Archyde The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treating type 2 diabetes (T2D) is rapidly increasing globally, driven by the rising prevalence of T2D adn obesity. these medications have proven benefits for cardiovascular health, kidney function, and reducing fatty liver disease. However, concerns have been raised about a potential link between GLP-1 … Read more
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines Fortune HHS Provides $590 Million to Accelerate Pandemic Influenza mRNA-based Vaccine Development, Enhance Platform Capability for Other Emerging Infectious Disease HHS.gov Moderna Receives $590 Million From HHS to Develop Bird Flu Vaccine Drug Topics How Prepared Are We For Avian Influenza? Contagionlive.com … Read more
Victor Mocanu, MD Credit: Research Gate People with psoriatic arthritis (PsA) and ankylosing spondylitis (AS), particularly in rural settings, frequently utilized emergency departments (Eds) for less and non-urgent health concerns, highlighting the need for more accessible health services in these areas.1 “Greater accessibility to ambulatory services may mitigate emergency department (ED) presentations for lower acuity … Read more
Archyde A shift in Coronary Prevention: Declining Aspirin Use Among High-Risk Individuals new research sheds light on a concerning trend in the use of aspirin for preventing cardiovascular disease. While aspirin has long been a go-to medication for mitigating heart attack adn stroke risk, recent findings suggest a downward trend in its usage, especially among … Read more
Timothy S. Anderson, MD Credit: University of Pittsburgh An analysis of preventive aspirin trends by atherosclerotic cardiovascular disease (ASCVD) risk revealed that self-reported primary prevention aspirin use decreased among older adults and adults with low ASCVD risk, but additionally among adults with higher ASCVD risk.1 Evidence-based recommendations released by the American College of Cardiology/American Heart … Read more
Andrew C. Stokes, PhD Credit: Boston University Patient factors, including sociodemographic, healthcare, and clinical elements, were linked to the initiation of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), in a population with obesity without type 2 diabetes (T2D).1 Among more than 97,000 commercially insured adults in a recent cohort study, approximately 2.0% began semaglutide … Read more
Sizheng Steven Zhao, MBChB, PhD Credit: LinkedIn JAK inhibitor (JAKi) therapy was not associated with an increased risk of cardiovascular disease, venous thromboembolism (VTE), or some cancers in people with psoriatic arthritis (PsA) and spondyloarthritis (SpA) compared to TNF inhibitors (TNFi) or IL-17 inhibitors (IL-17i).1 “Compared to TNFi, tofacitinib was shown to increase risk of … Read more
New research is providing clinicians with an overview of the association between cardiovascular health and the risk of developing metabolic dysfunctional-associated steatotic liver disease (MASLD).1 Leveraging National Health and Nutrition Examination Survey (NHANES) 2017-March 2020 data and using the American Heart Association (AHA)’s Life’s Essential 8 (LE8) score as a benchmark of cardiovascular health, investigators … Read more
Orrin M. Troum, MD, Credit: University of Southern California Pegloticase (Krystexxa; Amgen) was not found to put patients with gout at a higher risk of thromboembolic (TE) and cardiovascular (CV) events, according to a new post-hoc analysis of multiple trials assessing the therapy.1 “In these trials, the proportion of patients experiencing gout flares increased during … Read more
Unveiling the Unique Pathologies of IgA Nephropathy and Nephrotic Syndrome New research is shedding light on notable differences in the clinicopathological characteristics and long-term prognosis of patients with… The post New Research on IgA Nephropathy and Nephrotic Syndrome: Differences in Clinical Features and Long-Term Prognosis appeared first on NewsyList. Source link